Pregnancy Clinical Trial
Official title:
Intrauterine Cleaning After Placental Delivery at Cesarean Section: a Randomized Controlled Trial
PURPOSE:
To test the hypothesis that omission of intrauterine cleaning during cesarean deliveries
does not increase intraoperative and postoperative complications.
METHODS:
We plan to randomize 206 women undergoing primary and repeat cesarean deliveries to cleaning
(n=103) versus no cleaning (n=103) of the uterine cavity following placental delivery. Women
will be excluded if any of the following criteria are encountered: preterm premature rupture
of membranes, spontaneous rupture of membranes prior to cesarean section, chorioamnionitis,
fetal demise, uncontrolled diabetes or an immunosuppressive disorder. Primary outcome
measure will be endo-myometritis after delivery. Secondary outcomes will include post partum
hemorrhage, mean surgical time, retained products of conception, retained placenta,
quantitative blood loss, length of hospital stay, return of gastrointestinal function,
repeat surgery, and hospital readmission rates. Analysis will follow the intention-to-treat
principle.
GENERAL DESIGN All eligible patients who are scheduled for cesarean section at the Sparrow
hospital/Michigan State University Resident OBGYN and Perinatology clinics will be evaluated
for study inclusion. Patients meeting this study's inclusion criteria and lack exclusion
criteria will be approached for consent and enrollment.
Background
Caesarean section is the most common major surgical procedure performed in obstetric
practice. The American College of Obstetricians and Gynecologists (ACOG) estimates that in
2011 alone, one in three women who gave birth in the United States did so by cesarean
delivery. Compared to vaginal births, the increasing rate of caesarean births worldwide is a
well known cause of maternal morbidity, including hemorrhage, anesthetic complications,
shock, cardiac arrest, acute renal failure, assisted ventilation, venous thromboembolism and
increased risk of major postpartum infection.
With increasing cesarean section rates and its associated complications, obstetricians are
challenged to reduce perioperative and postoperative morbidity by adapting their surgical
skills and techniques. Over the years, randomized clinical trials have tried to answer many
questions surrounding the safety of several cesarean section techniques that impart maternal
morbidity. For example, the optimal type of cesarean section skin incision, whether or not
to create a bladder flap, one layer versus two later closure of the uterus, irrigating the
abdominal cavity, closure versus non closure of the parietal peritoneum, and suture versus
staples for skin closure at cesarean section.
Cleaning the uterine cavity following cesarean section is a routine practice by many
obstetricians. To ensure that the entire placenta and membranes are removed after delivery
of the placenta at cesarean, the uterine cavity is usually cleaned with one hand holding a
dry sponge to remove any remaining membranes or placental tissue, while the other hand is
placed on the fundus to stabilize the uterus. However, despite the lack of evidence to
support a policy of routine intrauterine cleaning after placental delivery at cesarean
section, the benefits of intrauterine cleaning as a routine practice during cesarean
sections remains uncertain. Obstetricians who do not routinely clean the uterine cavity
after placental delivery argue that this procedure is not performed routinely after vaginal
deliveries, and thus is a justification not to do so during cesarean sections..
To date, there has been no study, including randomized clinical trials that has answered
this very important question, hence the importance of this trial.
Objective:
The goal of this study is to employ a well designed randomized controlled clinical trial to
compare the efficacy of cleaning versus not cleaning the uterine cavity after placental
delivery at cesarean section. We hypothesize that omission of intrauterine cleaning during
cesarean deliveries does not increase intraoperative and postoperative complications
Our primary outcome measure will be endomyometritis after delivery. Endomyometritis will be
diagnosed by the presence of two or more of the following: abnormally tender uterus on
examination, temperature more than 38.0°C at any time postoperatively, and unexplained
maternal tachycardia more than 100 beats per minute (bpm). A diagnosis of endomyometritis
will be criteria for initiating treatment with antibiotics. Secondary outcomes will include
post partum hemorrhage, mean surgical time, retained products of conception, retained
placenta, quantitative blood loss, length of hospital stay, return of gastrointestinal
function, repeat surgery, and hospital readmission rates
Potential Contribution:
This study may show an optimal method for dealing with the uterine cavity after placental
delivery. The results may show in the long run whether routine cleaning of the uterine
cavity following placental delivery is beneficial or not.
METHODS:
Timeline: Once this study is approved we plan on recruiting patients for 18 months. Once our
recruitment period is complete we will perform data collection and analysis for two months.
We have an estimated end date 3-4 months after recruitment has completed.
Recruitment: All eligible patients for cesarean section at the Sparrow hospital/Michigan
State University OBGYN resident Clinic and OBGYN patients of the Sparrow Perinatal Center
will be evaluated for study inclusion. All patients meeting the study's inclusion criteria
and lack exclusion criteria will be approached for consent and enrollment. Patients will be
given a consent form to review at home prior to their admission for cesarean section. For
unscheduled patients, consent will be sought following the physician's decision to proceed
with cesarean section. Patients will have adequate time to consider enrollment and discuss
options with their physician prior to cesarean section. All eligible patients who present to
labor and delivery for cesarean section will be examined upon presentation.
After inclusion criteria have been met, the patient will be approached for consent to
participate in the study. Patients will be given study information and the consent form to
review. Consent will be documented by the patient's signature indicating understanding and
agreement to participate in the study.
Procedures: Patients admitted for cesarean section and meeting inclusion criteria will be
approached for consent. Consented patients will then be randomized into two groups.
Group 1: (Cleaning the uterine cavity): These participants will have their uterine cavities
cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol,
the uterus will be explored with one hand holding a sponge to remove any remaining membranes
or placental tissue, while the other hand is placed on the fundus to stabilize the uterus.
Group 2: (Not cleaning the uterine cavity): These participants will have their uterine
cavities left alone after complete delivery of the placenta. The placenta will be inspected
after delivery to make sure it is complete, including the membranes.
Assignment will be performed by opening a sequentially numbered opaque envelope containing
computer-randomized individual allocations. The envelope will be opened by the circulation
nurse in the operating room and silently viewed by the surgeons prior to surgery.
Instructions will be given to not verbalize the treatment arm revealed. The original
randomization will be performed by research staff before the initiation of the study using a
random number table generator, and the participants will be blinded to treatment once
assigned. Information regarding basic demographic data, interventions during the cesarean
delivery and postpartum course will be obtained from the participant's charts after
discharge from the hospital. The protocol for labor management will be the same for both
groups (for laboring patients), including continuous electronic fetal monitoring with the
external Doppler device. Per standard operative management at Sparrow Hospital/Michigan
State University, both groups will undergo inspection of the uterine incision, with or
without closure of the vesicouterine peritoneum (bladder flap), abdominal peritoneum, or
rectus muscles per attending preference. Both groups will undergo standard closure of the
abdominal fascia, consisting of suturing with a running non locking delayed absorbable
suture. Irrigation of the subcutaneous tissues superior to the closed fascia will be
performed in both groups. Staples or absorbable suture will be used for skin closure. In
addition, all participants will receive a standardized dose of 1-2 g cefazolin intravenously
as antibiotic prophylaxis before the start of surgery. Participants with cefazolin allergy
will receive 900 mg clindamycin.
Informed Consent: All eligible patients undergoing cesarean delivery at Sparrow hospital
will be given study information and the consent form to review. Consent will be documented
by the patient's signature indicating understanding and agreement to participate in the
study.
Sources of Materials: Data to be abstracted from the participant's charts will include
demographic information (age, race, socioeconomic status), obstetric characteristics
(parity, gestational age, indication for cesarean section, membrane status at time of
cesarean section, and post operative complications as listed above). To protect patient
confidentiality, only individuals directly involved in the study will have access to
identifiable private patient information.
Data Security: Patient confidentiality will be protected by making sure that only
individuals involved in the study will have access to identifiable patient information.
Collected information will be coded and stripped of identifiers.
Statistical analysis: Analysis will be based on intention-to-treat. A Cox proportional
hazard model will be used to estimate the hazards ratios between the two groups and will be
adjusted for confounders. The proportional hazard assumption will be checked graphically by
plotting the log-log of the survival probability and confirmed using Schoenfeld residuals.
Comparison of other continuous variables will be done by independent t-test and categorical
variables will be compared by the chi-squared test or Fisher exact test as appropriate.
Interval data and non- parametric testing will be analyzed with the Mann-Whitney U test. The
95% confidence intervals (CIs) will be reported throughout. A significance level of 0.05
will be used when significance testing was necessary. Logistic regression will be used to
analyze for potential confounding in the analysis of the primary outcome. The predetermined
analysis will be to include in the model variables that appeared not to be randomly
distributed during the randomization, as well as variables thought to be potential
confounders clinically. Analyses will be performed using STATA version 13.0 (Stata Corp,
College Station, TX).
Sample Size estimation:
After reviewing the literature, we considered a 20% reduction between groups to be
clinically significant. We used a 20% difference and a type 1 error rate of 0.05 and a power
of 0.90 for a two sided test. This will require randomization of 206 women (103 patients in
each group) to obtain an adequate sample size.
Assessment of Risks and benefits Subject Characteristics: Pregnant women with a singleton or
multiple pregnancies, vertex or breech presentation with intact membranes presenting to our
labor and delivery unit for an elective cesarean section will be eligible for participation.
We anticipate enrolling a minimum of 206 patients. Women will be excluded if any of the
following criteria are encountered: preterm premature rupture of membranes, spontaneous
rupture of membranes prior to cesarean section, chorioamnionitis, fetal demise, uncontrolled
diabetes or an immunosuppressive disorder. The involvement of pregnant women in this study,
a vulnerable population, is inevitable since cesarean section is a procedure performed only
in this patient population. The study will be restricted to Sparrow Hospital/Michigan State
University.
Benefits: The study is not designed to provide direct benefits to research participants.
However, if the hypothesis is true, participants in the study group may enjoy the benefit.
Since the anticipated risks to participants are minimal, the risks to subjects are
reasonable in relation to the anticipated benefits. The knowledge gained from this study has
the potential of significantly impacting obstetrical clinical practice. It will provide
evidence that can be used in decision making and options presented to women at cesarean
section. The results, if our hypothesis is true, will contribute to the long term goal of
providing safe efficacious options during cesarean section, which will reduce morbidity,
cost of health care and length of hospital stay.
Potential Risks: Just like all cesarean sections, patients are at risk of hemorrhage,
chorioamnionitis, anesthetic complications, hemorrhagic shock, cardiac arrest, acute renal
failure, assisted ventilation, venous thromboembolism and post operative infections. In this
study, even though we will not be cleaning the uterine cavity, we will ensure that the
placenta and membranes are removed in its entirety.
Protection against Risks: Major risks above and beyond those incurred with standard medical
care are not anticipated with this protocol. Cesarean section is a common procedure in
obstetrical practice. Not cleaning the uterine cavity during cesarean section is standard of
care by some of the attendings here at Sparrow. Safety will be monitored by the
investigators. In the case of an adverse event, it will be submitted to the Human research
Protection Office (HRPO) here at Sparrow per standard HRPO reporting guidelines.
Data and Safety Monitoring Plan: Although the risks to study participants are expected to be
minimal and no greater than those associated with routine cesarean sections, a number of
measures are planned to ensure patient safety. Monitoring will involve the principal
investigator who will monitor, document, and report to the Institutional Review Board, any
adverse events among study participants.
Data and Safety and Monitoring - Dr Maude Guerin will serve as the consultant for this
research study. She will be tasked with ensuring the overall safety of the subjects enrolled
in the study. She will be responsible for interpreting results of the interim analysis and
making decisions including stopping the study.
Interim analysis- Interim efficacy analysis will be conducted with endometritis as the
primary outcome of interest. Analyses will be performed by the study statistician and
presented to the DSMB. The board will make a recommendation regarding further conduct of the
study. The principal investigator will not be informed of the results of the interim
analysis unless the DSMB determines that some level of unblinding is necessary to make final
decisions about the conduct of the study. Possible decisions include stopping the study
because efficacy has been achieved or because futility, and modifying sample size.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Completed |
NCT02523755 -
Evaluation of Regional Distribution of Ventilation During Labor With or Without Epidural Analgesia
|
Phase 4 |